<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1730">
  <stage>Registered</stage>
  <submitdate>29/10/2007</submitdate>
  <approvaldate>29/10/2007</approvaldate>
  <nctid>NCT00551343</nctid>
  <trial_identification>
    <studytitle>Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome</studytitle>
    <scientifictitle>Contribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects With Prader-Willi Syndrome.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>X07-0178</secondaryid>
    <secondaryid>H07/045</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prader-Willi Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Learning disabilities</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Exenatide

Other: PWS - 

Other: Controls - 


Treatment: drugs: Exenatide
10ug Exenatide single s.c. injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>satiety hormones</outcome>
      <timepoint>1 day</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>appetite (visual analogue scale) insulin secretion</outcome>
      <timepoint>1 day</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  see below</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Diabetes mellitus, acute infections</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2008</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Garvan Institute of Medical Research - Darlinghurst Sydney</hospital>
    <postcode>2010 - Darlinghurst Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Garvan Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to investigate the effects of a GLP-1 agonist on satiety
      hormones in patients with Prader-Willi Syndrome (genetic defect causing obesity).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00551343</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lesley V Campbell, Prof</name>
      <address>Garvan Institute of Medical Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Lisa Sze, MD</name>
      <address />
      <phone>++61 2 9295 8214</phone>
      <fax />
      <email>l.sze@garvan.org.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>